Impact of various vaccine boosters on neutralization against omicron following prime vaccinations with inactivated or adenovirus-vectored vaccine.
Impact of various vaccine boosters on neutralization against omicron following prime vaccinations with inactivated or adenovirus-vectored vaccine.
复制标题
灭活疫苗或腺病毒载体疫苗初次接种后，各种疫苗加强剂对 omicron 中和作用的影响
DOI：
10.1016/j.scib.2022.05.010
复制
发表时间：
2022-07-15
期刊：
影响因子：
18.9
通讯作者：
Sun, Yufa
中科院分区：
文献类型：
--
作者：
Huang, Qingrui;Zeng, Jiawei;Lang, Qingyun;Gao, Feng;Liu, Dejun;Tian, Siyu;Shi, Rui;Luo, Ling;Wang, Hao;Hu, Liping;Jiang, Linrui;Liu, Yawei;Li, Kailiang;Wu, Yunbo;Xu, Junjie;Jiang, Wenxi;Guo, Ning;Chen, Zhihai;Hao, Xiaohua;Jin, Ronghua;Yan, Jinghua;Sun, Yufa
在撰写本文时，世界正在经历一场巨大的SARS-CoV-2 Omicron变种感染浪潮。两种SARS-CoV-2灭活疫苗（IAV，Sinovac的CoronaVac和Sinopharm的BBIBP-CorV），两剂疫苗接种方案，一种重组蛋白亚单位疫苗（PRV，ZF 2001，安徽智飞隆康），采用三剂疫苗接种方案和一剂重组腺病毒载体疫苗（AdV，康信的Convidecia）已获得中国有条件批准用于一般公众用途或紧急用途[1]。这四种疫苗构成了中国疫苗接种计划的核心。据报道，Omicron广泛逃避疫苗中和，加强注射似乎是必要的[2，3]。在我国目前疫苗接种计划的背景下，迫切需要找到一种上级加强策略来对抗Omicron变异株，考虑到疫苗在我国的广泛使用，本研究旨在探讨什么样的加强策略可以最大限度地提高Omicron变异株的中和作用。本研究已获得中国科学院微生物研究所伦理委员会的审查和批准（APIMCAS 2021159）。部分血清标本来自北京地坛的一项单中心、开放标签、随机对照临床试验
As of this writing, the world is currently experiencing a huge wave of infection with the Omicron variant of SARS-CoV-2. Two SARS-CoV-2 inactivated vaccines (IAVs, CoronaVac by Sinovac and BBIBP-CorV by Sinopharm) with a two-dose vaccination regimen, one recombinant protein subunit vaccine (PRV, ZF2001 by Anhui Zhifei Longcom) with a three-dose vaccination regimen, and one single-dose recombinant adenovirus-vectored vaccine (AdV, Convidecia by CanSino) have been given conditional approval for general public use or approved for emergency use by China [1]. These four vaccines form the core of China’s vaccination program. It has been reported that Omicron extensively escapes vaccine neutralization, and a booster shot seems to be necessary [2, 3]. It is urgent to discover a superior booster strategy in China’s current vaccination program context to fight against the Omicron variant.Considering the wide use of vaccines in China, this study aims to investigate what booster strategy can maximally improve neutralization against the Omicron variant. The study has been reviewed and approved by the Ethics Committee of the Institute of Microbiology of the Chinese Academy of Sciences (APIMCAS2021159). Some serum specimens were from a single-center, open-label, and randomized controlled clinical trial at Beijing Ditan
登录
查看更多内容
影响因子：
82.9
作者：
Khoury, David S.;Cromer, Deborah;Davenport, Miles P.
通讯作者：
Davenport, Miles P.
COVID-19疫苗对轻度和重度疾病的保护持续时间。
DOI：
10.1056/nejmoa2115481
发表时间：
2022-01-27
期刊：
The New England journal of medicine
影响因子：
--
作者：
Andrews N;Tessier E;Stowe J;Gower C;Kirsebom F;Simmons R;Gallagher E;Thelwall S;Groves N;Dabrera G;Myers R;Campbell CNJ;Amirthalingam G;Edmunds M;Zambon M;Brown K;Hopkins S;Chand M;Ladhani SN;Ramsay M;Lopez Bernal J
通讯作者：
Lopez Bernal J
影响因子：
64.5
作者：
Dejnirattisai W;Huo J;Zhou D;Zahradník J;Supasa P;Liu C;Duyvesteyn HME;Ginn HM;Mentzer AJ;Tuekprakhon A;Nutalai R;Wang B;Dijokaite A;Khan S;Avinoam O;Bahar M;Skelly D;Adele S;Johnson SA;Amini A;Ritter TG;Mason C;Dold C;Pan D;Assadi S;Bellass A;Omo-Dare N;Koeckerling D;Flaxman A;Jenkin D;Aley PK;Voysey M;Costa Clemens SA;Naveca FG;Nascimento V;Nascimento F;Fernandes da Costa C;Resende PC;Pauvolid-Correa A;Siqueira MM;Baillie V;Serafin N;Kwatra G;Da Silva K;Madhi SA;Nunes MC;Malik T;Openshaw PJM;Baillie JK;Semple MG;Townsend AR;Huang KA;Tan TK;Carroll MW;Klenerman P;Barnes E;Dunachie SJ;Constantinides B;Webster H;Crook D;Pollard AJ;Lambe T;OPTIC Consortium;ISARIC4C Consortium;Paterson NG;Williams MA;Hall DR;Fry EE;Mongkolsapaya J;Ren J;Schreiber G;Stuart DI;Screaton GR
通讯作者：
Screaton GR
影响因子：
64.8
作者：
Cele S;Jackson L;Khoury DS;Khan K;Moyo-Gwete T;Tegally H;San JE;Cromer D;Scheepers C;Amoako DG;Karim F;Bernstein M;Lustig G;Archary D;Smith M;Ganga Y;Jule Z;Reedoy K;Hwa SH;Giandhari J;Blackburn JM;Gosnell BI;Abdool Karim SS;Hanekom W;NGS-SA;COMMIT-KZN Team;von Gottberg A;Bhiman JN;Lessells RJ;Moosa MS;Davenport MP;de Oliveira T;Moore PL;Sigal A
通讯作者：
Sigal A